4BASEBIO UK SOCIETAS Market Cap ($998.55K)
Market Cap & Net Worth: 4BASEBIO UK SOCIETAS (4BB)
4BASEBIO UK SOCIETAS market cap. 4BASEBIO UK SOCIETAS (LSE:4BB) has a market capitalization of $998.55K (GBX8.21 Billion) as of November 8, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30669 globally and #812 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 4BASEBIO UK SOCIETAS's stock price GBX530.00 by its total outstanding shares 15484875 (15.48 Million). Also see 4BB cash generation efficiency for how efficiently the company converts equity into cash flow.
4BASEBIO UK SOCIETAS Market Cap History (2021–2026)
4BASEBIO UK SOCIETAS market cap history from 2021 to 2026. Data shows growth from $1.16 Million to $998.55K (8.21% CAGR). Check 4BASEBIO UK SOCIETAS stock quote for real-time trading data and today's change.
Index Memberships
4BASEBIO UK SOCIETAS is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$990.01 Million | 0.10% | #159 of 722 |
Weight: 4BASEBIO UK SOCIETAS's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
4BASEBIO UK SOCIETAS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 4BASEBIO UK SOCIETAS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 4BB net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.68x
4BASEBIO UK SOCIETAS's market cap is 0.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.16 Million | $338.00K | -$3.23 Million | 3.43x | N/A |
| 2022 | $1.34 Million | $268.00K | -$5.15 Million | 4.99x | N/A |
| 2023 | $1.28 Million | $506.00K | -$7.67 Million | 2.53x | N/A |
| 2024 | $2.28 Million | $933.00K | -$12.33 Million | 2.44x | N/A |
| 2025 | $1.16 Million | $1.69 Million | -$16.91 Million | 0.68x | N/A |
Competitor Companies of 4BB by Market Capitalization
Companies near 4BASEBIO UK SOCIETAS in the global market cap rankings as of November 8, 2026. Also see 4BB total asset value for a full breakdown of the balance sheet.
Key companies related to 4BASEBIO UK SOCIETAS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of 4BASEBIO UK SOCIETAS (2021–2026)
Market capitalization of 4BASEBIO UK SOCIETAS from 2021 to today. Between 2021 and today, 4BASEBIO UK SOCIETAS's market cap moved from $1.16 Million to $ 998.55K, with a yearly change of 8.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX998.55K | -13.82% |
| 2025 | GBX1.16 Million | -49.17% |
| 2024 | GBX2.28 Million | +77.94% |
| 2023 | GBX1.28 Million | -4.23% |
| 2022 | GBX1.34 Million | +15.45% |
| 2021 | GBX1.16 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of 4BASEBIO UK SOCIETAS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $998.55K USD |
| MoneyControl | $998.55K USD |
| MarketWatch | $998.55K USD |
| marketcap.company | $998.55K USD |
| Reuters | $998.55K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About 4BASEBIO UK SOCIETAS
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for u… Read more